COVID-19 and Low Molecular Weight Heparin (LMWH)

Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.

Thromboembolic complications are a common and costly medical problem, associated with significant morbidity and mortality, especially in postoperative patients. There have been reports of death due to thromboembolic complications even after short procedures, e.g. arthroscopy. Low-molecular-weight heparins (LMWHs) (e.g., certoparin, dalteparin, enoxaparin, nadroparin, reviparin, tinzaparin) have...

Novel Subcutaneous Sustained Release Nanoparticles Encapsulating Low Molecular Weight Heparin (lmwh): Preparation, Characterization and Evaluation

Objective: The objective of the current research work was to prepare and evaluate novel subcutaneous sustained release polymeric nanoparticles for low molecular weight heparin (LMWH). Methods: In this study, we prepared subcutaneously administered polymeric nanoparticles encapsulating LMWH using different grades of polycaprolactons (PCL) (14k, 45k, 80k) and 0.1% Polyvinyl alcohol (PVA) solution...

Low Molecular Weight Heparin Overdose: A 10 Year Case Series

  Background: Low molecular weight heparin (LMWH) is used for the treatment and prevention of coagulative disorders. Few patients receiving therapeutic doses of LMWH develop major hemorrhage. Currently there are few reports in the literature on acute overdose on adults.  In this study, clinical profile, treatment and outcome of 21 patients who acutely overdosed enoxaparin are described. Method...

Low molecular weight heparin.

Heparin and low-molecular-weight heparin.

Heparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have repl...